Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

Inclusion criteria

• Female subjects between 18 and 65 years of age, inclusive.
• Female subjects of non-childbearing potential including non-pregnant, non-lactating, and either postmenopausal or surgically sterile for at least 45 days post procedure.
• Within BMI range 18.5 to </= 29.9 kg/m^2, inclusive.
• In good health, as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.
• Receive an explanation of the mandatory pharmacogenomic (PgX) component of the study.

Exclusion criteria

• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.
• Previous history of adverse reaction to statins.
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) in Period 1.
• Use of systemic hormone replacement therapy within 1 year prior to Check-in (Day -1).
• History of use of tamoxifen, aromatase inhibitor or any other endocrine agent for treatment of breast cancer.
• Female subject is pregnant lactating, or breast feeding.